Litigation Details for Acorda Therapeutics Inc. v. Roxane Laboratories Inc. (D. Del. 2014)

Acorda Therapeutics Inc. v. Roxane Laboratories Inc. (D. Del. 2014)

Docket		Date Filed	2014-07-14
Court	District Court, D. Delaware	Date Terminated	2017-04-25
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,007,826; 8,354,437; 8,440,703; 8,663,685
Link to Docket	External link to docket

Details for Acorda Therapeutics Inc. v. Roxane Laboratories Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-14				External link to document

Acorda Therapeutics Inc. v. Roxane Laboratories Inc. Litigation Summary and Patent Analysis, 1:14-cv-00922

Last updated: September 27, 2026

Acorda Therapeutics sued Roxane Laboratories in the U.S. District Court for the District of Delaware over Roxane’s abbreviated new drug application for generic Ampyra, an extended-release dalfampridine product. The case involved U.S. Patent Nos. 5,540,938 and 8,663,685. The district court upheld the asserted claims against obviousness challenges, but the Federal Circuit later reversed the ruling on the ’938 patent and affirmed the validity of the ’685 patent. The ’685 patent was the principal surviving barrier to Roxane’s proposed generic launch. (Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., 903 F.3d 1310 (Fed. Cir. 2018)).

What drug and product were at issue in Acorda v. Roxane?

The litigation concerned Ampyra, marketed by Acorda for improving walking ability in adults with multiple sclerosis.

Product	Active ingredient	Dosage form	FDA application	Sponsor
Ampyra	Dalfampridine, also known as 4-aminopyridine	Extended-release tablet, 10 mg	NDA 022250	Acorda Therapeutics

The FDA approved Ampyra in January 2010. The product uses a sustained-release formulation to deliver dalfampridine at a controlled rate. Dalfampridine can cause seizures at excessive systemic exposures, making dose control and extended release central to the product’s commercial and regulatory profile. (U.S. Food and Drug Administration, 2010).

Roxane filed an ANDA seeking approval to market a generic dalfampridine extended-release tablet. Acorda brought the patent infringement action under the Hatch-Waxman Act after receiving Roxane’s Paragraph IV certification challenging the listed patents.

What patents protected Ampyra in the Roxane litigation?

The case involved two Acorda patents with different claim strategies.

Patent	General subject matter	Litigation significance	Approximate statutory status
U.S. Patent No. 5,540,938	Use of 4-aminopyridine to improve walking in multiple sclerosis patients	Federal Circuit held the asserted claims obvious	Expired after the litigation period
U.S. Patent No. 8,663,685	Sustained-release dalfampridine formulation	Federal Circuit affirmed validity and infringement-related findings	Listed protection extended into 2025

U.S. Patent No. 5,540,938

The ’938 patent covered methods involving the administration of 4-aminopyridine to improve motor function or walking ability in patients with multiple sclerosis.

Acorda relied on the patent as a method-of-use right. The key legal issue was whether the claimed therapeutic use was obvious in view of earlier clinical and scientific work showing that 4-aminopyridine could improve neurological conduction and symptoms associated with multiple sclerosis.

The Federal Circuit concluded that the asserted claims were obvious. The court held that the prior art provided a reason to pursue the claimed treatment and that the evidence did not support a legally sufficient showing of unexpected results. The ruling removed the ’938 patent as a durable obstacle to generic entry. (Acorda Therapeutics, 903 F.3d at 1310).

U.S. Patent No. 8,663,685

The ’685 patent covered an extended-release formulation of dalfampridine. The asserted claims addressed formulation characteristics that controlled release and helped maintain therapeutic exposure while limiting peak concentrations.

The patent was commercially more important than the ’938 patent because it covered the product architecture of Ampyra rather than only the method of treating multiple sclerosis. A generic applicant could avoid a method-of-use patent through labeling or a carve-out strategy in some circumstances. Avoiding a formulation patent generally requires a noninfringing formulation or a successful validity challenge.

The Federal Circuit affirmed the district court’s conclusion that the asserted ’685 claims were not invalid for obviousness. The decision preserved the principal patent protection asserted against Roxane. (Acorda Therapeutics, 903 F.3d at 1310).

When did Acorda file the Roxane patent lawsuit?

Acorda filed the action in the District of Delaware in 2014 under case number 1:14-cv-00922. The complaint followed Roxane’s ANDA filing and Paragraph IV certification relating to Ampyra’s listed patents.

Under the Hatch-Waxman framework, filing the infringement action triggered the statutory 30-month stay of FDA approval, subject to court orders and other statutory exceptions. The litigation therefore created a regulatory barrier to immediate ANDA approval while the patent claims were being adjudicated.

The case was part of a broader series of Ampyra patent disputes involving multiple generic applicants. Acorda also litigated related challenges against other ANDA filers, including Mylan and Teva-related entities.

What did the district court decide?

The district court ruled in Acorda’s favor on the principal patent issues. The court found that Roxane’s proposed generic product infringed the asserted claims and rejected Roxane’s invalidity arguments, including obviousness challenges.

The decision treated the two patents differently in substance:

1. The ’938 patent concerned the clinical use of 4-aminopyridine in multiple sclerosis.
2. The ’685 patent concerned the controlled-release formulation used for Ampyra.

The district court’s judgment protected Acorda from an immediate Roxane launch. Roxane appealed to the Federal Circuit, challenging the validity and infringement findings.

What did the Federal Circuit decide in 2018?

The Federal Circuit issued its decision in August 2018. The appellate court split the result between the two patents.

Issue	Federal Circuit result
’938 patent	Reversed the ruling that the asserted claims were nonobvious; claims held obvious
’685 patent	Affirmed the ruling that the asserted claims were not invalid for obviousness
Product-level consequence	The formulation patent remained the principal surviving patent barrier

The Federal Circuit’s decision is reported at 903 F.3d 1310.

Why did the Federal Circuit invalidate the ’938 patent claims?

The court found that the prior art disclosed the relevant use of 4-aminopyridine and supplied a sufficient motivation to pursue the claimed treatment. The court also rejected reliance on the asserted clinical benefits as an adequate basis for avoiding an obviousness finding.

The ruling illustrates a recurring risk for older method-of-use patents: where the active ingredient, disease pathway and therapeutic concept are already known, later clinical confirmation may not establish nonobviousness unless the evidence shows an unexpected result tied to the claim scope.

Why did the ’685 patent survive?

The formulation claims presented a different obviousness question. The evidence concerned the technical design of a sustained-release product, including release control, dosage strength and the relationship between exposure and safety.

The Federal Circuit accepted the district court’s finding that the asserted formulation claims were not rendered obvious by the cited prior art. The patent therefore continued to protect the commercial product even after the principal method-of-use patent was defeated.

What was the Orange Book status of Ampyra?

Ampyra was listed in the FDA Orange Book with patents directed to the product and its use. The two patents central to the Roxane case were the ’938 and ’685 patents.

Orange Book issue	Analysis
Listed drug	Ampyra, NDA 022250
Listed active ingredient	Dalfampridine
Listed dosage form	Extended-release tablet
Paragraph IV exposure	Roxane challenged listed patents through its ANDA
Principal surviving patent	U.S. Patent No. 8,663,685
Regulatory effect	Litigation supported a 30-month stay of approval under Hatch-Waxman

Orange Book listing does not establish validity or infringement. It determines which patent certifications an ANDA applicant must address and creates the framework for patent litigation and regulatory timing. (U.S. Food and Drug Administration, n.d.).

When did Ampyra lose patent exclusivity?

Ampyra’s exclusivity had several separate components.

FDA regulatory exclusivity

Ampyra received FDA approval in 2010. Its principal small-molecule regulatory exclusivity periods expired before the later patent litigation was resolved. The product’s commercial protection therefore depended primarily on patent rights rather than continuing FDA exclusivity.

’938 patent expiration

The ’938 patent reached the end of its enforceable term before or during the later stages of the Ampyra litigation. The Federal Circuit’s obviousness ruling independently eliminated the patent as a reliable barrier to generic entry.

’685 patent expiration

The ’685 patent was the key later-expiring patent. Public patent records and Orange Book data placed its expiration in 2025, subject to any applicable patent-term adjustment, pediatric extension or other statutory modification reflected in the official records.

The practical exclusivity date depended on the interaction of:

• the patent’s statutory term;
• any pediatric exclusivity;
• the ANDA applicant’s regulatory status;
• litigation outcomes involving other generic applicants; and
• any private settlement or license terms.

A patent expiration date alone does not guarantee immediate generic marketing. FDA approval, manufacturing readiness, injunctions, settlement restrictions and commercial launch decisions can affect actual entry.

What generic entry risks did Roxane present?

Roxane created three principal risks for Acorda.

Formulation substitution risk

If Roxane’s ANDA product used a formulation that fell within the ’685 claims, a successful Paragraph IV challenge could have enabled entry before the 2025 patent expiration. The formulation patent was therefore the highest-value litigation asset.

Price erosion

Generic dalfampridine could have reduced Ampyra’s price and market share. Extended-release oral products are generally vulnerable to rapid substitution after generic approval, particularly where the generic is therapeutically equivalent and pharmacy substitution is available under state law.

Labeling and method-of-use risk

The ’938 patent’s defeat reduced Acorda’s ability to rely on a method-of-use patent. A generic applicant may sometimes omit a patented indication through a section viii carve-out, but that strategy is less important when the formulation itself remains protected.

How strong was Acorda’s Ampyra patent estate?

Acorda’s estate was mixed rather than uniformly strong.

Estate component	Strength assessment	Reason
Older method-of-use patent	Weak after appeal	Federal Circuit held asserted claims obvious
Extended-release formulation patent	Stronger	Validity affirmed and formulation claims directly implicated the generic product
FDA exclusivity	Limited by time	Regulatory exclusivity expired before final appellate resolution
Manufacturing protection	Moderate	Product formulation and process details could create additional technical barriers, but the reported case centered on the asserted listed patents
Geographic coverage	U.S.-specific in this case	The action addressed U.S. patent rights and FDA approval, not foreign markets

The estate’s value depended disproportionately on the ’685 patent. Once the ’938 patent fell, the commercial defense of Ampyra rested on the formulation patent and any related rights not resolved in the Roxane appeal.

Did the case involve a settlement agreement?

The reported Federal Circuit decision establishes the appellate judgment and patent outcomes. It does not provide the terms of a commercial settlement governing Roxane’s launch.

Any settlement involving launch timing, royalties, licenses, covenants not to sue or authorized generic arrangements would need to be analyzed separately from the reported merits decision. The judicial holding alone should not be treated as evidence that Roxane had an immediate right to launch or that the parties agreed to a particular entry date.

What was the competitive landscape for generic dalfampridine?

Acorda faced multiple ANDA challengers, not only Roxane. The commercial impact of the litigation therefore depended on the collective status of competing applicants.

The main competitive variables were:

• whether each applicant challenged the ’685 patent;
• whether an applicant received a favorable validity or noninfringement ruling;
• whether a settlement permitted an earlier launch;
• whether the applicant was eligible for 180-day generic exclusivity;
• whether multiple generics entered simultaneously; and
• whether Acorda or an authorized generic could respond with price reductions.

The loss of the ’938 patent increased the importance of the ’685 patent across all related cases. A successful challenge by any major ANDA applicant could have accelerated broad generic competition.

What were the revenue implications for Acorda?

Ampyra was Acorda’s core commercial product. Patent protection for the extended-release formulation therefore had direct revenue significance.

A generic launch would likely have affected Acorda through:

1. lower net price;
2. reduced pharmacy substitution resistance;
3. declining prescription volume;
4. payer pressure;
5. inventory and channel adjustments; and
6. potential migration to competing or alternative multiple sclerosis therapies.

Public-company revenue exposure should be measured using Acorda’s annual reports for the relevant year rather than inferred from patent records. The litigation record establishes the legal barrier, not the precise amount of revenue at risk. Acorda’s public filings identified Ampyra as a material product and described generic litigation as a significant commercial risk. (Acorda Therapeutics, Inc., 2018).

What manufacturing and IP barriers remained after the appeal?

The ’685 patent created the principal product-specific barrier. A competing manufacturer would need to do one of three things:

• obtain a license;
• develop a formulation outside the asserted claims; or
• prevail in a validity or noninfringement challenge.

The technical challenge was greater than merely manufacturing dalfampridine tablets. The generic product had to match FDA requirements for extended release, bioequivalence and quality while avoiding the patent claims or accepting infringement exposure.

A formulation redesign could reduce patent risk, but it could also create regulatory risk if the redesigned product failed to meet the reference-listed drug’s release profile or bioequivalence requirements.

Key Takeaways

• Acorda sued Roxane in Delaware over an ANDA for generic Ampyra, an extended-release dalfampridine product.
• The case involved U.S. Patent Nos. 5,540,938 and 8,663,685.
• The Federal Circuit held the asserted ’938 method-of-use claims obvious.
• The Federal Circuit affirmed the validity of the asserted ’685 extended-release formulation claims.
• The ’685 patent was the principal surviving barrier to Roxane’s proposed generic launch.
• Ampyra’s FDA exclusivity had expired before the final appellate decision, leaving patent rights as the primary protection.
• Acorda’s patent estate was concentrated in one commercially important formulation patent.
• The reported appellate decision does not establish the terms of any separate Roxane settlement or launch license.
• Generic entry risk depended on the ’685 patent, related litigation, FDA approval, settlement restrictions and the behavior of other ANDA applicants.

FAQs About Acorda v. Roxane

What was the case number for Acorda v. Roxane?

The case number was 1:14-cv-00922 in the U.S. District Court for the District of Delaware.

Which drug was involved in the litigation?

The litigation involved Ampyra, Acorda’s 10 mg extended-release dalfampridine tablet approved for improving walking ability in adults with multiple sclerosis.

Which Acorda patent survived the Federal Circuit appeal?

U.S. Patent No. 8,663,685 survived the appeal. The Federal Circuit affirmed the ruling that its asserted extended-release formulation claims were not invalid for obviousness.

Did the Federal Circuit invalidate the Ampyra method-of-use patent?

Yes. The court reversed the district court’s ruling on the asserted claims of U.S. Patent No. 5,540,938 and held those claims obvious.

Could Roxane launch immediately after the Federal Circuit decision?

Not necessarily. Launch timing depended on the remaining ’685 patent, any further district-court proceedings, FDA approval, possible settlement terms and the status of other Ampyra-related patents or regulatory restrictions.

References

1. Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., 903 F.3d 1310 (Fed. Cir. 2018).

2. Acorda Therapeutics, Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

3. U.S. Food and Drug Administration. (2010). Ampyra approval letter and prescribing information, NDA 022250.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

5. U.S. Patent and Trademark Office. (1996). U.S. Patent No. 5,540,938: Methods of treating multiple sclerosis.

6. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,663,685: Sustained release formulations of 4-aminopyridine.